Crinetics Pharmaceuticals, Inc.

The European Medicines Agency has started reviewing for potential pan-EU marketing authorization 15 new drugs, including Novo Nordisk’s semaglutide for the treatment of non-cirrhotic metabolic dysfunc

Not even two months into the new year and some of the expected biggest-earning new drugs of 2025 have already been approved. An updated analysis conducted by Scrip and Evaluate Pharma of drugs expec

Biopharma financing during the fourth quarter of 2024 totaled $16.8bn from 251 deals. Of those, 60 reached $100m or more. The follow-on public offering (FOPO) and venture financing categories tied for

Neurocrine Biosciences will soon launch its second wholly owned commercial product, Crenessity (crinecerfont) for classic congenital adrenal hyperplasia (CAH), adding what the company sees as another